

# Correction: *HLA* Polymorphisms Are Associated With Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia



Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji, and Shinya Kimura

In the original version of this article (1), The HLA profile in panel B of Fig. 2 was inadvertently mislabeled. The error has been corrected in the online HTML and PDF versions of the article. The authors regret this error.

## Reference

1. Ureshino H, Shindo T, Tanaka H, Saji H, Kimura S. *HLA* polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. *Mol Cancer Ther* 2021;20:142-9.

---

Published online May 4, 2022.

*Mol Cancer Ther* 2022;21:855

doi: 10.1158/1535-7163.MCT-22-0146

©2022 American Association for Cancer Research